Bank of America’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$75.8M Buy
900,871
+107,176
+14% +$7.78M 0.01% 1319
2025
Q4
$59.9M Buy
793,695
+399,783
+101% +$25.2M ﹤0.01% 1431
2025
Q3
$15.7M Sell
393,912
-115,075
-23% -$4.39M ﹤0.01% 2845
2025
Q2
$22.1M Buy
508,987
+83,107
+20% +$3.16M ﹤0.01% 2455
2025
Q1
$15.9M Buy
425,880
+320,340
+304% +$12.4M ﹤0.01% 2694
2024
Q4
$4.78M Sell
105,540
-193,932
-65% -$9.89M ﹤0.01% 3635
2024
Q3
$17.6M Sell
299,472
-50,084
-14% -$2.4M ﹤0.01% 2526
2024
Q2
$13.8M Sell
349,556
-47,222
-12% -$2.29M ﹤0.01% 2620
2024
Q1
$26.4M Sell
396,778
-92,431
-19% -$4.04M ﹤0.01% 2010
2023
Q4
$13.7M Buy
489,209
+468,639
+2,278% +$9.39M ﹤0.01% 2542
2023
Q3
$438K Buy
+20,570
New +$453K ﹤0.01% 5400

Other funds holding APGE

Bank of America's APGE Position: Q1 2026 in Review

Bank of America increased its Apogee Therapeutics (APGE) stake by 14% in Q1 2026, buying an estimated $7.78M and bringing the position to 900,871 shares worth $75.8M. The position accounts for 0.01% of the portfolio, ranked #1319.

Bank of America first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Bank of America held 900,871 shares of Apogee Therapeutics worth $75.8M as of Q1 2026.
  • Bank of America bought 107,176 Apogee Therapeutics shares in Q1 2026, an estimated $7.78M.
  • Apogee Therapeutics made up 0.01% of Bank of America's portfolio in Q1 2026, its #1319 holding.
  • Bank of America first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.